

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0771**

Inventors: **Bennett et al.**

Serial No.: **Not Yet Assigned**

Filing Date: **Herewith**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Title: **Antisense Modulation of Inducible Nitric
Oxide Synthase Expression**

"Express Mail" Label No. **EL976562694US**
Date of Deposit **September 5, 2003**

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop Sequence, P. O.
Box 1450, Alexandria, VA 22313-1450.

By *Jane Massey Licata*
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/490,208, filed January 24, 2000 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: September 5, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0771	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant C. Frank Bennett et al.	
		Filing Date herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Bereta et al., Inhibitory effect of di-catechol rooperol on VCAM-1 and iNOS expression in cytokine-stimulated endothelium, <i>Life Sci.</i> , 1997, 60:325-334	
	AB	Cai et al., Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection, <i>Int. J. Cardiol.</i> , 1995, 50:243-251	
	AC	Cartwright et al., Inhibition of nitric oxide synthase by antisense techniques: investigations of the roles of NO produced by murine macrophages, <i>Br. J. Pharmacol.</i> , 1997, 120:146-152	
	AD	Casey et al., Skin allograft rejection in mice lacking inducible nitric oxide synthase, <i>Transplantation</i> , 1997, 64:589-593	
	AE	Corbett et al., Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets, <i>Am. J. Physiol.</i> , 1996, 270:C1581-1587	
	AF	Corbett et al., The Use of Aminoguanidine, a Selective iNOS Inhibitor, to Evaluate the Role of Nitric Oxide in the Development of Autoimmune Diabetes, <i>Methods</i> , 1996, 10:21-30	
	AG	Ding et al., Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice, <i>J. Immunol.</i> , 1998, 160:2560-2564	
	AH	Ding et al., Antisense blockade of inducible nitric oxide synthase in glial cells derived from adult SJL mice, <i>Neurosci. Lett.</i> , 1996, 220:89-92	
	AI	Geller et al., Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes, <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1993, 90:3491-3495	
	AJ	Giovine et al., Synthesis and characterization of a specific peptide nucleic acid that inhibits expression of inducible NO synthase, <i>FEBS Lett.</i> , 1998, 426:33-36	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. ISPH-0771	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant C. Frank Bennett et al.	
		Filing Date herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AK	Hoque et al., Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS, Am. J. Physiol., 1998, 275:H1078-1083	
	AL	Kroncke et al., Inducible nitric oxide synthase in human diseases, Clin. Exp. Immunol., 1998, 113:147-156	
	AM	Laubach et al., Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death, Proc. Natl. Acad. Sci. U. S. A., 1995, 92:10688-10692	
	AN	Lee et al., Cytokine Regulation of iNOS Expression in Human Glial Cells, Methods, 1996, 10:31-37	
	AO	MacMicking et al., Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase, Cell, 1995, 81:641-650	
	AP	Maier et al., Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression, Biochim. Biophys. Acta., 1994, 1208:145-150	
	AQ	Marletta et al., Catalysis by nitric oxide synthase, Curr. Opin. Chem. Biol., 1998, 2:656-663	
	AR	Noiri et al., In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia, J. Clin. Invest., 1996, 97:2377-2383	
	AS	Park et al., Preactivation exposure of RAW 264.7 cells to taurine chloramine attenuates subsequent production of nitric oxide and expression of iNOS mRNA, J. Leukoc. Biol., 1997, 61:161-166	
	AT	Peresleni et al., Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury, Am. J. Physiol., 1996, 270:F971-977	
	AU	Rabinovitch et al., Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS-expressing cells and relationships to cytokines expressed in the islets, Endocrinology, 1996, 137:2093-2099	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. ISPH-0771	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant C. Frank Bennett et al.	
		Filing Date herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AV	Roland et al., Gadolinium chloride inhibits Kupffer cell nitric oxide synthase (iNOS) induction, <i>J. Leukoc. Biol.</i> , 1996, 60:487-492	
	AW	Schini-Kerth et al., N-alpha-tosyl-L-lysine chloromethylketone prevents expression of iNOS in vascular smooth muscle by blocking activation of NF-kappa B, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 1997, 17:672-679	
	AX	Selleri et al., Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells, <i>Br. J. Haematol.</i> , 1997, 99:481-489	
	AY	Vejlstrup et al., Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure [In Process Citation], <i>J. Mol. Cell. Cardiol.</i> , 1998, 30:1215-1223	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified	Docket No. TSPH-0771	Serial No.
List of Patents and Publications Cited by Application (Use several sheets if necessary)	Applicant C. Frank Bennett et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	5,789,395	08/04/1998	Amin et al.	514	152
	AB	5,695,761	12/09/1997	Denhardt et al.	424	184.1
	AC	5,216,025	06/01/1993	Gross et al.	514	565
	AD	5,028,627	07/02/1991	Kilbourn et al.	514	565
	AE	5,850,004	12/15/1998	MacMicking et al.	800	2
	AF	5,766,909	06/16/1998	Xie et al.	435	189
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES NO
	AO	WO 93/13055	07/08/1993	PCT	X
	AP	WO 98/04132	02/05/1998	PCT	X
	AQ	WO 96/19440	06/27/1996	PCT	X
	AR	WO 98/30220	07/16/1998	PCT	X
	AS	WO 98/48826	11/05/1998	PCT	X
	AT	WO 98/34626	08/13/1998	PCT	X
	AU	EP 630649	12/28/1994	EPC	X
	AV				
	AW				
	AX				

EXAMINER	DATE CONSIDERED
----------	-----------------